Attached files

file filename
EX-4.9 - DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF - GWG Holdings, Inc.f10k2019ex4-9_gwghold.htm
EX-99.4 - THE BENEFICIENT COMPANY GROUP, L.P. AND SUBSIDIARIES - GWG Holdings, Inc.f10k2019ex99-4_gwghold.htm
EX-99.2 - PORTFOLIO OF LIFE INSURANCE POLICIES AS OF DECEMBER 31, 2019 - GWG Holdings, Inc.f10k2019ex99-2_gwghold.htm
EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO - GWG Holdings, Inc.f10k2019ex32-1_gwghold.htm
EX-31.2 - CERTIFICATION - GWG Holdings, Inc.f10k2019ex31-2_gwghold.htm
EX-31.1 - CERTIFICATION - GWG Holdings, Inc.f10k2019ex31-1_gwghold.htm
EX-23.2 - CONSENT OF BAKER TILLY VIRCHOW KRAUSE, LLP - GWG Holdings, Inc.f10k2019ex23-2_gwghold.htm
EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - GWG Holdings, Inc.f10k2019ex23-1_gwghold.htm
EX-21 - LIST OF SUBSIDIARIES - GWG Holdings, Inc.f10k2019ex21_gwghold.htm
10-K - ANNUAL REPORT - GWG Holdings, Inc.f10k2019_gwgholdings.htm

Exhibit 99.1

 

 

February 24, 2020

 

GWG Life, LLC

325 North St. Paul Street, Suite 2650

Dallas TX 75201

United States of America

 

Dear Sirs

 

Re:GWG Life Settlements Portfolio – Quarterly Valuation as of December 31, 2019

 

You have asked that we prepare a valuation of your portfolio as of the Valuation Date set out in Appendix A. Terms used in this letter and not otherwise defined herein have the meaning specified in your Subscription Agreement with us or on the ClariNet LS website.

 

Assumptions and Reliance

In preparing this valuation, we have relied upon the accuracy of the data contained in your ClariNet LS account as of the Pricing Date specified in Appendix A.
We have performed no testing of such data to determine its accuracy or completeness.
We have prepared this valuation solely with respect to the Portfolio identified in Appendix A as of the Pricing Date.
We have used assumptions as to discount rates and survival curve construction which have been specified by you and which are set out in Appendix B.
We have assumed that you have independently determined that the premium schedule used to value each Case is sufficient to carry the relevant Policy through to maturity.
The survival curves used in valuation have been generated by reference to mortality factors and underwriting dates supplied by you. We understand that these mortality factors reflect your determination of the Longest LE for the relevant Insured (as defined in Appendix C). We have not made any independent investigation of this determination.

 

Valuation

 

Based on the composition of the Portfolio as of the Pricing Date, we find that the Net Present Value of the Portfolio on the Valuation Date is as specified in Appendix A.

 

Yours faithfully

 

CLEARLIFE LIMITED

 

By: /s/ Mark Venn  
Name:  Mark Venn  
Title: CEO  

  

ClearLife Limited, Triscombe House, Triscombe, Taunton TA4 3HG, United Kingdom
Tel. +44 (0)20 7100 0600 / info@clearlifeltd.com / www.clearlifeltd.com
ClearLife Limited is a company registered in England & Wales. Registration number 06424296
Registered office: Priory House, Pilgrims Court, Sydenham Road, Guildford GU1 3RX

 

 

 

 

 

Appendix A

Valuation Inputs and Outputs

 

Description   Current Quarter   Previous Quarter
Valuation Date   December 31, 2019   September 30, 2019
Pricing Date:   February 24, 2020   October 31, 2019
ClariNet LS Portfolio Name:   2019 Q4 Portfolio Snapshot FIX  

2019 Q3 Valuation

Snapshot

Total Face Amount:   $2,051,210,598   $2,095,307,569
Total Net Death Benefit:   $2,020,972,961   $2,064,155,926
Number of Active Policies:   1,151   1,174
Discount Rate:   8.25%   8.25%
Net Present Value:   $796,038,991   $807,518,088

 

Definitions

Total Face Amount: this is the sum of the Face Amounts for each Case included in the Portfolio on the Valuation Date.
Total Net Death Benefit: This is the Net Death Benefit on the Valuation Date for each Case included in the Portfolio as of the Pricing Date. This excludes any Retained Death Benefit (“RDB”) amounts. Where the Case has a RDB amount which varies over time, the number shown here reflects the RDB amount as of the Valuation Date. The Net Death Benefit associated with each Case may vary over time and may not equal the Face Amount for the relevant Case.
Number of Active Policies: This is the number of Cases in the Portfolio on the Valuation Date with a Status other than MAT, PEND, SOLD, EXP, SURR or LAPS.
Number of Unique Surviving Insureds: This is the number of unique surviving Insureds referenced by the Active Policies in the Portfolio on the Valuation Date. This number may be fewer than the Number of Active Policies, where a single Insured is referenced by more than one Active Policy.
Net Present Value: This is the sum of the net present values calculated on the Pricing Date for all Active Policies in the Portfolio on the Valuation Date, determined by discounting the future mortality-adjusted cashflows back to the Valuation Date at the Discount Rate.

 

2

 

 

 

Appendix B

Valuation Template Settings

 

Parameter Name   Current Quarter   Previous Quarter
Fees Template   Zero Fees   Zero Fees
Q(x) Adjustment   None   None
Mortality Table Name   2015 ANB   2015 ANB
Improvement Rates   0%   0%
Survival Factor Interpolation Type   Piecewise Constant Qx   Piecewise Constant Qx
Interpolate VBT Table Row Based on DOB at LE Review Date   False   False
Calculation of Joint Life Survival Curve   Frasierized   Frasierized
Smoking Status Override   Non-smoker   Non-smoker
LE Calculation Type   Mean   Mean
Calculation of LE Review Date Given Multiple Reports   Blended   Blended
NDB Collection Lag in Months   0   0
Longevity Calculation Type   Monthly   Monthly
Number of months to stress Qx   0   0
Interest payment during NDB collection lag   None   None
User-defined NDB collection lag interest rate   0%   0%
Aging underwriter reports   Regular   Regular
Apply Table Improvement from Underwriting Date   False   False
Blending methodology when combining life expectancy reports   Lx   Lx
Apply Improvement Rate Before Mortality Calculation   False   False
Set Value Date to next Policy monthiversary   True   True
Set LE Report Date(s) to Policy monthiversary   True   True
Include Other Purchase Costs in IRR   True   N/A
Include Origination Fee in IRR   True   N/A
Subtract the specified number from the Mean LE50   0   N/A

 

Appendix C

Longest LE Definition

 

Longest LE: The LE Estimate used for each Policy within the Portfolio for purposes of calculating A2E analytics and Fair Market Value prospectively:

 

For any Policy owned as of December 31, 2018 that was purchased prior to LE underwriting changes by ITM TwentyFirst Services in 2013, the longer of the two LEs utilized in the valuation of the Policy following receipt of the updated LEs ordered in response to the 2013 changes;
For any Policy owned as of December 31, 2018 that was purchased after the LE underwriting changes by ITM TwentyFirst Services in 2013, the longest LE on file that was utilized in the pricing of the Policy at the closing of the Policy purchase (in instances where additional LE Reports were ordered, these were incorporated into the analysis whether in receipt of the LE Report at the time of closing or not, so long as the LE Report was received by a date no more than 30 calendar days subsequent to the closing date of the Policy purchase); and
For any Policy purchased subsequent to December 31, 2018 (i.e. future purchases for purposes of the initial A2E analysis), the longest life expectancy utilized in the pricing of the Policy at the closing of the Policy purchase so long as the LE Report is received by a date no more than 30 calendar days subsequent to the closing date of the Policy purchase.

 

 

3